- Home
- STRO vs TCRX Comparison
STRO vs TCRX Comparison
Compare STRO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- TCRX
- Stock Information
- Founded
- STRO 2003
- TCRX 2018
- Country
- STRO United States
- TCRX United States
- Employees
- STRO N/A
- TCRX N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- TCRX Health Care
- Exchange
- STRO Nasdaq
- TCRX Nasdaq
- Market Cap
- STRO 292.6M
- TCRX 257.5M
- IPO Year
- STRO 2018
- TCRX 2021
- Fundamental
- Price
- STRO $2.89
- TCRX $4.41
- Analyst Decision
- STRO Strong Buy
- TCRX Strong Buy
- Analyst Count
- STRO 7
- TCRX 5
- Target Price
- STRO $12.14
- TCRX $11.40
- AVG Volume (30 Days)
- STRO 596.9K
- TCRX 261.6K
- Earning Date
- STRO 11-13-2024
- TCRX 11-12-2024
- Dividend Yield
- STRO N/A
- TCRX N/A
- EPS Growth
- STRO N/A
- TCRX N/A
- EPS
- STRO N/A
- TCRX N/A
- Revenue
- STRO $160,955,000.00
- TCRX $9,362,000.00
- Revenue This Year
- STRO N/A
- TCRX N/A
- Revenue Next Year
- STRO N/A
- TCRX $3.10
- P/E Ratio
- STRO N/A
- TCRX N/A
- Revenue Growth
- STRO 230.90
- TCRX N/A
- 52 Week Low
- STRO $2.13
- TCRX $3.73
- 52 Week High
- STRO $6.13
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- STRO 32.85
- TCRX 34.37
- Support Level
- STRO $4.01
- TCRX $5.03
- Resistance Level
- STRO $4.60
- TCRX $6.23
- Average True Range (ATR)
- STRO 0.36
- TCRX 0.43
- MACD
- STRO -0.06
- TCRX -0.05
- Stochastic Oscillator
- STRO 3.93
- TCRX 5.22
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.